poisar

Stocks · News reference

Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39

BenzingaBenzinga Newsdesk

Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $35 to $39.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncMesoblast Limited

    Mesoblast Showcased at ASX Premier Investor Day Event

    Mesoblast Limited presented at the ASX Investor Day in Melbourne, highlighting its transformation into a commercial-stage biotechnology company. The company outlined key value-creation priorities including expansion of its FDA-approved Ryoncil® therapy into adult acute graft-versus-host disease, advancement of rexlemestrocel-L for inflammatory chronic low back pain and cardiopulmonary indications, and disciplined capital deployment for commercial growth and late-stage development programs.

  2. Fiscal.ai

    Mesoblast Highlighted at ASX Investor Day

    Mesoblast Limited participated in the Australian Securities Exchange (ASX) Investor Day in Melbourne, presenting on its transition to a commercial-stage biotechnology company.

  3. Globenewswire IncMesoblast Limited

    Mesoblast Board Changes

    Mesoblast Limited announced board changes with the retirement of William Burns (after 12 years) and Philip Krause (since 2022). The company plans to recruit new directors with U.S. and global commercial expertise as it transitions to a revenue-generating commercial enterprise following the FDA approval and successful U.S. launch of Ryoncil® for pediatric steroid-refractory acute graft versus host disease.